Zealand Pharma to host conference call in relation to the release of the Annual Report for 2011
Zealand Pharma A/S
Zealand Pharma to host conference call in relation to the release of the Annual
Report for 2011
Copenhagen, 2012-03-09 13:00 CET (GLOBE NEWSWIRE) -- Zealand Pharma A/S (NASDAQ
OMX Copenhagen: ZEAL), a Danish biotechnology company dedicated to the
discovery and development of innovative peptide drugs, will release its Annual
Report for 2011 and announce full-year financial results on Thursday, 15 March
2012 before 9:00 CET.
On the day of results, David Solomon, President and Chief Executive Officer,
Mats Blom, Chief Financial Officer and Hanne Leth Hillman, Vice President for
IR and Corporate Communication, will host a conference call at 14:00 CET/ 9:00
EDT to present the 2011 Annual Report. The call will include a Q&A session.
The conference call will be conducted in English and the dial-in numbers are:
Denmark: +45 3272 9273
UK and international: +44 (0) 20 3003 2666
US: +1 866 966 5335
A live broadcast of the conference call including the related slide
presentation will be screened at the following link
(http://livecast.se/stockontv/120315/zealandpharma/) and participants are
recommended to register approximately 15 minutes ahead of the presentation.
A replay of the event will also be made available on the Zealand Pharma’s
website following the broadcast (ir.zealandpharma.com).
# # #
For further information, please contact:
Hanne Leth Hillman, Vice President for IR & Corporate Communication,
Tel: +45 5060 3689,
About Zealand Pharma
Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biotechnology company based
in Copenhagen, Denmark with a mature clinical pipeline of innovative peptide
drugs. The company's lead invention is lixisenatide (Lyxumia® 1)), a once-daily
GLP-1 agonist licensed to Sanofi for the treatment of Type 2 diabetes. In
October, Sanofi submitted a marketing authorization application (MAA) for
lixisenatide in Europe and submission for regulatory approval in the United
States is expected in Q4 2012. Zealand Pharma also has a collaboration with
Boehringer Ingelheim covering dual acting glucagon/GLP-1 agonists, including
ZP2929, for the treatment of diabetes and obesity, and a license agreement with
Helsinn Healthcare on elsiglutide, a clinical stage GLP-2 drug for the
prevention of chemotherapy-induced diarrhea.
Zealand Pharma specializes in the discovery, optimization and development of
novel peptide drugs, and all drug candidates in its pipeline have been
identified through the company's own drug discovery activities. Zealand
Pharma's products target disease areas where existing treatments fail to
adequately serve patient needs and where the market potential for improved
treatments through the use of peptide drugs is high.
For further information: www.zealandpharma.com.
Note 1) Lyxumia® is the intended trademark for lixisenatide. Lixisenatide is
not currently approved or licensed anywhere in the world.